Literature DB >> 18762806

Progress and prospects: genetic engineering in xenotransplantation.

S Le Bas-Bernardet1, I Anegon, G Blancho.   

Abstract

In this review, we summarize the work published over the last 2 years using genetic modifications of animals in the field of xenotransplantation. Genetic engineering of the donor has become a powerful tool in xenotransplantation, both for the inactivation of one particular porcine gene and for the addition of human genes with the goal of overcoming xenogeneic barriers. We summarize the work relative to the knockout of the alpha1,3-galactosyltransferase gene, followed by genetic engineering aimed at reducing the humoral and cellular immune response, complement activation and coagulation. Finally, we report on the genetic modification of pigs to reduce porcine endogenous retrovirus infection risk in the xenogeneic context.

Entities:  

Mesh:

Year:  2008        PMID: 18762806     DOI: 10.1038/gt.2008.119

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

Review 1.  Porcine models of digestive disease: the future of large animal translational research.

Authors:  Liara M Gonzalez; Adam J Moeser; Anthony T Blikslager
Journal:  Transl Res       Date:  2015-01-13       Impact factor: 7.012

2.  Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors.

Authors:  Takele Argaw; Winston Colon-Moran; Carolyn Wilson
Journal:  Xenotransplantation       Date:  2016-03-29       Impact factor: 3.907

3.  Bortezomib, C1-inhibitor and plasma exchange do not prolong the survival of multi-transgenic GalT-KO pig kidney xenografts in baboons.

Authors:  S Le Bas-Bernardet; X Tillou; J Branchereau; N Dilek; N Poirier; M Châtelais; B Charreau; D Minault; J Hervouet; K Renaudin; C Crossan; L Scobie; Y Takeuchi; M Diswall; M E Breimer; N Klar; M R Daha; P Simioni; S C Robson; M B Nottle; E J Salvaris; P J Cowan; A J F d'Apice; D H Sachs; K Yamada; I Lagutina; R Duchi; A Perota; G Lazzari; C Galli; E Cozzi; J-P Soulillou; B Vanhove; G Blancho
Journal:  Am J Transplant       Date:  2015-02       Impact factor: 8.086

Review 4.  Contribution of large pig for renal ischemia-reperfusion and transplantation studies: the preclinical model.

Authors:  S Giraud; F Favreau; N Chatauret; R Thuillier; S Maiga; T Hauet
Journal:  J Biomed Biotechnol       Date:  2011-03-03

5.  Porcine Knock-in Fibroblasts Expressing hDAF on α-1,3-Galactosyltransferase (GGTA1) Gene Locus.

Authors:  Ji Woo Kim; Hye-Min Kim; Sang Mi Lee; Man-Jong Kang
Journal:  Asian-Australas J Anim Sci       Date:  2012-10       Impact factor: 2.509

6.  Production of α1,3-galactosyltransferase targeted pigs using transcription activator-like effector nuclease-mediated genome editing technology.

Authors:  Jung-Taek Kang; Dae-Kee Kwon; A-Rum Park; Eun-Jin Lee; Yun-Jin Yun; Dal-Young Ji; Kiho Lee; Kwang-Wook Park
Journal:  J Vet Sci       Date:  2016-03-22       Impact factor: 1.672

7.  Alpha-1,3-galactosyltransferase-deficient miniature pigs produced by serial cloning using neonatal skin fibroblasts with loss of heterozygosity.

Authors:  Young June Kim; Kwang Sung Ahn; Minjeong Kim; Min Ju Kim; Jin Seop Ahn; Junghyun Ryu; Soon Young Heo; Sang-Min Park; Jee Hyun Kang; You Jung Choi; Hosup Shim
Journal:  Asian-Australas J Anim Sci       Date:  2016-03-30       Impact factor: 2.509

8.  Highly efficient multiplex genetic engineering of porcine primary fetal fibroblasts.

Authors:  Benjamin Klapholz; Heather Levy; Ramesh Kumbha; Nora Hosny; Michael E D'Angelo; Bernhard J Hering; Christopher Burlak
Journal:  Surg Open Sci       Date:  2020-11-18

9.  Grand challenges in alloimmunity and transplantation.

Authors:  Antoine Toubert
Journal:  Front Immunol       Date:  2011-08-29       Impact factor: 7.561

10.  Identification by mass spectrometry and immunoblotting of xenogeneic antigens in the N- and O-glycomes of porcine, bovine and equine heart tissues.

Authors:  Chunsheng Jin; Reeja Maria Cherian; Jining Liu; Heribert Playà-Albinyana; Cesare Galli; Niclas G Karlsson; Michael E Breimer; Jan Holgersson
Journal:  Glycoconj J       Date:  2020-06-15       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.